
To: **Professor David Kerr, University of Oxford**
Dr Rachel Midgley, University of Oxford

Oncology Clinical Trials Office (OCTO)
Department of Clinical Pharmacology
Old Road Campus Research Building
University of Oxford, Old Road Campus, off Roosevelt Drive
Headington, Oxford, OX3 7DQ, UK

From: **Dr. Niko Andre**
Dr. Belguendouz Bendahmane
Dr. Florin Sirzen

F. Hoffmann-La Roche Ltd.
PBMO
Grenzacherstrasse
4070 Basel

Date: 23 April 2009

Dear Professor Kerr, Dear Doctor Midgley,

We wish to inform you that the NSABP C-08 study has not met its primary endpoint of improving Disease-Free Survival (DFS) in patients with early colon cancer following surgery.

The C-08 study is a phase III randomised, multi-centre study designed to measure DFS as primary endpoint in patients with resected stage II or III adenocarcinoma of the colon. Patients enrolled in the study were randomised to receive treatment with adjuvant Avastin[®] every two weeks for six months in combination with mFOLFOX6 chemotherapy, followed by Avastin[®] alone every two weeks for an additional six months, or chemotherapy alone for six months.

No new unexpected safety events were observed.

These topline results will be further analysed by the National Surgical Adjuvant Breast and Bowel Project (NSABP) who are responsible for running the C-08 trial. Other trials investigating the use of Avastin immediately following surgery, including other studies in early colon cancer, are not affected.

We would like to take this opportunity to sincerely thank you for your continuing commitment and support of the ongoing QUASAR2 study.

Yours sincerely,

Dr. Niko Andre
Avastin Medical Director

Dr. Belguendouz Bendahmane
Senior International Medical Leader Avastin GI

Dr. Florin Sirzen
Clinical Scientist Leader Avastin GI